PMC:7035340 / 457-752 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"22","span":{"begin":15,"end":23},"obj":"Species"},{"id":"23","span":{"begin":141,"end":149},"obj":"Species"},{"id":"31","span":{"begin":155,"end":174},"obj":"Disease"}],"attributes":[{"id":"A22","pred":"tao:has_database_id","subj":"22","obj":"Tax:9606"},{"id":"A23","pred":"tao:has_database_id","subj":"23","obj":"Tax:9606"},{"id":"A31","pred":"tao:has_database_id","subj":"31","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ethal, as most patients have mild symptoms and good prognosis1,2. However, according to the Chinese government’s daily report, 13.2–21.3% of patients with 2019-nCoV infection developed into severe or fatal illness (Fig. S1a), which is characterized by the rapid development to acute respiratory "}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T5","span":{"begin":155,"end":174},"obj":"Disease"},{"id":"T6","span":{"begin":165,"end":174},"obj":"Disease"}],"attributes":[{"id":"A5","pred":"mondo_id","subj":"T5","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"ethal, as most patients have mild symptoms and good prognosis1,2. However, according to the Chinese government’s daily report, 13.2–21.3% of patients with 2019-nCoV infection developed into severe or fatal illness (Fig. S1a), which is characterized by the rapid development to acute respiratory "}